EGFR-TKI

PreclinicalSmall molecule

SShanghai Pulmonary Hospital, Shanghai, China

EGFR-TKI is one of 129 small molecule programs targeting Targeted Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Targeted TherapyCompleted

Lung CancerActive, not recruiting

AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Targeted TherapyPreclinical

Completed

Lung CancerPreclinical

Active, not recruiting

AdenocarcinomaPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 3

34 2

Erbitux

IImclone

Phase 3

41 3

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

2 4

Ds-1062a

Daiichi Sankyo

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Advanced NSCLC

NCT04324164

Q3 2031

Not yet recruiting

Lung Cancer

NCT07338396

Clinical

Trials by Indication[1]

EGFR Mutation2 trials

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 3·NCT02859077·100 enrolled

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT03002844·50 enrolled

Completed·TTaichung Veterans General Hospital··NCT07267247·100 enrolled

Metastasis1 trial

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Unknown status·SSun Yat-sen University·Phase 3·NCT02714010·601 enrolled

6 more indications

Targeted Therapy1 trial

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Completed·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·N/A·NCT04552613·114 enrolled

Hypofractionated Radiotherapy1 trial

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Unknown status·FFirst People's Hospital of Hangzhou·Phase 2·NCT02788058·76 enrolled

Treatment1 trial

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03389256·144 enrolled

Lung Cancer1 trial

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine··NCT07338396·3,000 enrolled

Adenocarcinoma1 trial

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Unknown status·SShanghai University of Traditional Chinese Medicine··NCT01745302·470 enrolled

Advanced NSCLC1 trial

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Recruiting·HHunan Province Tumor Hospital··NCT04324164·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for EGFR-TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EGFR-TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EGFR-TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

EGFR-TKI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2031

Trials by Indication[1]

EGFR Mutation2 trials

Pneumonitis1 trial

Brain Metastases1 trial

Non-Small Cell Lung Cancer1 trial

Metastasis1 trial

Targeted Therapy1 trial

Hypofractionated Radiotherapy1 trial

Treatment1 trial

Lung Cancer1 trial

Adenocarcinoma1 trial

Advanced NSCLC1 trial

References

Drug Info

Quick Facts

Related News